Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- KDP +0.7% (reaffirms guidance),
Other news:
- NA +193.3% (announces $500 million convertible notes private placement for BNB treasury strategy)
- NKTR +27.8% (to announce top-line data from Phase 2b study)
- LIMN +7.8% (provides investor updates in presentation; is already in discussions with academic consortia to design expansion cohorts)
- AMRN +6.3% (signs exclusive license and supply agreement with Recordati to commercialize VAZKEPA in Europe)
- LAES +5.9% (SEALSQ Corp and WISeSat.Space launch new satellite with SpaceX)
- NUVB +4.9% (taletrectinib has been added as a Preferred Agent in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancers)
- BTM +4.3% (Chief Compliance Officer Mark Smalley departed from the Company)
- CIFR +4% (commences hashing at its Black Pearl site)
- PHAR +3.6% (to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis)
- CDTX +3.3% ($250 mln stock offering)
- ACNT +3.1% (to divest American Stainless Tubing)
- MA +2.5% (deepening its partnership with Fiserv (FI) to integrate its new FIUSD token across a range of Mastercard products and services)
- AMD +2.4% (AMD and and HCLTech forge strategic alliance to develop future-ready solutions across AI, digital and cloud)
- MPTI +2.1% (awarded $5.5 mln contract from top DoD contractor)
- SMCI +2.1% (prices offering of 2.0 bln of convertible senior notes due 2030)
- LQDA +1.8% (receives $50 mln from Healthcare Royalty)
- NVO +1.8% (CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM)
- THO +1.7% (re-authorization of $400 mln share buyback)
- FFBC +1.7% (to acquire Westfield Bancorp)
- ELLO +1.7% (provides update in connection with Exercise of Right of First Refusal for Dorad Energy Ltd. Shares)